Professor Xing-Jie Liang got Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH). He was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Professor Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and a principal investigator at Center for Excellence of Nanoscience, Chinese Academy of Sciences. Professor Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, member of American Society of Cell Biology and president of nanobiophysics committees of Chinese Biophysics Society. Professor Liang is current Editor-in-Chief of 《Current Drug Delivery》, Associate Editors of 《Biomaterials》 and 《Biophysics Report》; Advisory editorial board member of 《ACS Nano》; Editorial member of 《Biomaterials Research》, 《Theranostics》 and guest editor of 《Biotechnology Advances》 and 《Science in China: Life Sciences》.
Prof. Liang has published over 270 publications; H-index is over 59. His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vitro and in vivo, and novel strategies to increase therapeutic effect on cancers and infective diseases. Developing drug delivery strategies for prevention/treatment of cancers are current programs ongoing in Professor Liang's lab based on understanding of basic physio-chemical and biological processes of nanomedicine.